title: Signet-ring cell carcinoma of the prostate effectively treated with maximal androgen blockade.
abstract: Primary signet-ring cell carcinoma (SRCC) of the prostate is very rare and has a poor prognosis, even when treated with aggressive therapy. We report herein a case of a 72-year-old man with prostatic SRCC. The patient had a tumor that extended directly to the rectum. Maximal androgen blockade was started and 20 months later, the patient was alive without evidence of recurrence. The present case of prostatic SRCC responded well to medical therapy, however, tumors can recur after a long period of time. Therefore, adjuvant therapy is recommended.
authors.affiliation: Department of Urology, Sanjukai Hospital, Sapporo, Hokkaido, Japan. akagashi@sanjukai.or.jp
authors.forename: Keigo
authors.initials: K
authors.lastname: Akagashi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tanda
authors.forename: Shuji
authors.initials: S
authors.lastname: Kato
authors.forename: Shigeki
authors.initials: S
authors.lastname: Ohnishi
authors.forename: Hisao
authors.initials: H
authors.lastname: Nakajima
authors.forename: Akihito
authors.initials: A
authors.lastname: Nanbu
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Nitta
authors.forename: Mikio
authors.initials: M
authors.lastname: Koroku
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D018279:Carcinoma, Signet Ring Cell / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen; D016729:Leuprolide